Donated brain thrown out; Children's Wisconsin 'profoundly sorry'
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience.
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways
The Brief
Children's Wisconsin says it accidentally 'discarded' the frozen portion of a young woman's donated brain.
Ashtyn Fellenz, who died in December, underwent pioneering gene therapy 21 years ago.
The doctor who conducted the surgery in 2003 said the lost brain tissue was vital for ongoing gene therapy research.
WAUWATOSA, Wis. - When 24-year-old Ashtyn Fellenz died on December 5, 2024, the dry ice was waiting. She was already at Children's Wisconsin where a pathologist was prepared to carefully extract her brain and preserve it for future research.
A 'tremendous' loss
What we know
By all accounts, the extraction of her brain was flawless. It was separated into hemispheres - half of it chemically fixated in a formalin solution, the other half segmented and rapidly frozen. The plan was to quickly ship both halves to a Living BioBank at Children's Hospital in Dayton, Ohio. Instead, the tissue sat in a Children's Wisconsin laboratory for months.
Ashtyn Fellenz died on December 5, 2024, at age 24
Eventually, after internal administrative changes and a laboratory move, hospital officials discovered the frozen half of Ashtyn's brain had been accidentally "discarded."
The discovery stunned not only the Fellenz family, but the researcher who had requested the brain be preserved – Dr. Paola Leone.
"The loss is tremendous," Leone said.
A silent life
The backstory
Ashtyn was born on June 15, 2000, apparently healthy. By six months of age, her parents knew something was seriously wrong.
"She started missing milestones, not being able to lift up her head," said her father, Scott Fellenz.
Ashtyn was diagnosed with Canavan Disease, a rare genetic disorder that causes degeneration of the protective coating around nerves and a loss of white matter in the brain. Children with Canavan progressively lose the ability to use their muscles and become trapped inside their own bodies, like a living rag doll. Without intervention, most children with the disease die before age 10.
Just after her 3rd birthday, Ashtyn received gene therapy through a viral vector injected directly into her brain. The pioneering surgery was aimed at replacing the defective gene that causes Canavan disease with a functional gene.
In 2003, Ashtyn underwent pioneering surgery to inject a functional gene into her brain in hopes of replacing the defective one. The experimental gene therapy did not cure the disease, but Dr. Leone said it improved her quality of life and helped her survive until age 24.
"That sounds like a success," said FOX6 Investigator Bryan Polcyn.
"It is a success," Dr. Leone replied.
FREE DOWNLOAD: Get breaking news alerts in the FOX LOCAL Mobile app for iOS or Android
Ashtyn never spoke a word in her life, but Dr. Leone said there was a treasure trove of information inside her brain.
"In that silence, there was so much knowledge," the doctor said.
A big part of her legacy
What they're saying
Asthyn was one of 16 children to get the experimental treatment, but Dr. Leone said she is one of the rare Canavan patients to have died under optimal circumstances for preserving her brain.
"Most Canavan patients die at home," the doctor said. By the time their bodies are available for autopsy, the brain tissue has degraded significantly. Asthyn died at Children's Wisconsin.
"The scenario was perfect," Dr. Leone said. "She was in the hospital. The dry ice was there, ready to go."
Dr. Paola Leone, now a professor at Rowan University in New Jersey, performed the surgery in 2003.
Ashtyn's family had long ago agreed to donate her brain for research.
"I knew that's what we wanted to do," said Arlo Fellens, Ashtyn's mother.
"It was no question that we had to do that," said Scott Fellenz, her father. "It was a big part of her legacy."
Unexplained delays
Timeline
When Ashtyn died on Dec. 5, Children's Wisconsin determined that a previous consent form signed by her parents was outdated. Before the hospital could ship the brain to Ohio, they would need a new one.
Dr. Leone sent the updated consent hours before boarding a flight to Wisconsin to deliver a eulogy at Ashtyn's funeral.
"Her powerful voice encrypted in her DNA will deliver life-saving messages," Dr. Leone told a packed Pewaukee church, still believing the brain would soon be ready for her to evaluate.
What happened next is detailed in a series of emails between Dr. Leone and a pathologist at Children's.
"I mean, I gave the address, the FedEx number," Dr. Leone said. "Everything was ready to go."
Dr. Leone flew to Wisconsin to delivery a eulogy at Ashtyn's funeral on December 7, 2024
More than a month passed without any shipment.
On Jan. 13, Dr. Lauren Parsons, Director of Pathology at Children's Wisconsin, wrote an email thanking Dr. Leone for her "patience," adding that "holidays and some leadership transitions" had kept her busy.
Dr. Parsons wrote, "I fully endorse sending the brain" to Ohio. But two more months passed – still nothing.
"We follow up with emails, no reply," Dr. Leone said. "Other emails, no reply."
"She literally ghosted her for two months," Scott Fellenz said.
SIGN UP TODAY: Get daily headlines, breaking news emails from FOX6 News
Finally, in March, Arlo Fellenz contacted the hospital for answers. She received a call back from "grief services," asking to set up a meeting. Arlo knew the news would not be good, so she demanded to hear about it over the phone.
"They regret to tell me it was, her brain was disposed of," Arlo recalled hearing
"They threw your daughter's brain away," said FOX6 Investigator Bryan Polcyn.
"Yeah, that's what it comes down to," Arlo said. "They tossed out her brain. How can you do that with a brain?"
Actually, half of Ashtyn's brain was eventually shipped to Ohio – the fixed portion.
But it was the frozen half that was inadvertently thrown away. Dr. Leone said that was the most valuable part for research purposes.
"And I was like, 'How could you discard something so valuable?,' Arlo Fellenz said. "And they kept just saying, 'Well we're sorry. We just, it was just disposed of, we can't tell you anything more.'"
"It was literally like losing Ashtyn all over again," Scott Fellenz said.
It's irreplaceable
Dig deeper
For Dr. Leone, the loss is both personal and professional.
"When Ashton passed away we were all heartbroken," the doctor said.
Beyond the emotional ties she had to Ashtyn, Dr. Leone said the post-mortem examination of her brain would have offered unparalleled insights into how the gene therapy worked inside Ashtyn.
Arlo and Scott Fellenz have hired attorney James Gende to represent them.
"This would have just led, just paved the way for any other application of gene therapy into the brain to let us know if gene therapy can persist," the doctor said.
Dr. Leone said it would most likely have resulted in a "high-impact" publication that could have served future research.
"It's a loss of information that would have been precious and cited for the years to come, for the centuries to come, because this is the one and only specimen, not just for Canavan, for any other gene therapy," the doctor said. "It's irreplaceable."
We are 'profoundly sorry'
The other side
Children's Wisconsin declined a request for an on-camera interview. In a statement emailed to FOX6 Investigators, a spokesperson writes:
"We were honored to support Ashtyn's family's wish for her legacy to help others. As we communicated to the family when this error was discovered, and reiterate now, our team is profoundly sorry this happened, and we continue to take steps to reinforce our protocols to help ensure this does not occur again. The availability of human tissue to support life-changing and lifesaving medical research is critical to offering hope to families. We take seriously our work to support research through proper tissue collection, storage and usage. We are deeply grateful for Ashtyn's life and for her family's advocacy and care, and again offer our most sincere regret and apology."
After receiving the statement, FOX6 Investigators submitted 16 written questions to Children's Wisconsin seeking further detail. The hospital responded with this:
"As this situation is under the threat of litigation, and due to patient privacy matters, we are unable to respond in detail to many of your questions. We share the following in the hope it provides additional context:
We have comprehensive processes in place to properly manage tissue donated for research purposes. Aspects of those processes were not followed, which caused this error.
We realized this error as the sample was being prepared for shipment. While one portion of the tissue remained, it became apparent that the separate frozen portion of the tissue was erroneously disposed of.
To your question regarding timing, it appears several matters created the gap in time from when the autopsy occurred to when the tissue was approved for shipment (which is when we realized a portion was accidentally disposed of). Those factors included time needed to secure and review correct consent forms from the receiving institution, the move of the lab and various scheduling matters.
The change in lab leadership had no bearing on this matter.
None of the above is an excuse for the remaining tissue sample being accidentally disposed of and for the delay in realizing and communicating this error.
We have taken several specific steps to learn from this, including:The team has participated in re-education on our processes.This matter is being prioritized as it proceeds through our internal quality review process.Should the quality review process identify other areas for improvement, we will address those improvements with the seriousness they deserve.
The team has participated in re-education on our processes.
This matter is being prioritized as it proceeds through our internal quality review process.
Should the quality review process identify other areas for improvement, we will address those improvements with the seriousness they deserve.
This was a very unique situation. We cannot recall any previous situation where organ tissue donated for medical research was erroneously discarded."
Lawsuit imminent
What's next
The Fellenz family has hired attorney James Gende to represent them. If Asthyn's brain can't help with Canavan research, her family said perhaps money will.
"Then Ashtyn can have some meaning in her life after her death."
The family has set up a separate fund at St. Bartholomew's Episcopal Church in Pewaukee. According to the website, Ashtyn's Hope supports families and children with Canavan Disease with medical equipment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
West Nile Virus found in mosquitoes in Lubbock County, warns city. Here's what to know
The City of Lubbock is warning Lubbock County residents that West Nile Virus has been detected in mosquitoes in the county. According to the city, the Biological Threat Research Lab at Texas Tech University has notified the Lubbock Health Department that mosquitoes carrying West Nile Virus are active in Lubbock County. Others are reading: What's coming in Lubbock County's proposed budget? Here's what's being discussed In response, the vector control teams will increase spraying within the community, with the city strongly urging the public to take precautions to reduce mosquito bites and help prevent the spread of the virus. The city is also asking residents to help prevent the spread of the virus by reporting biting adult mosquitoes or reporting a suspected mosquito breeding site. According to the health department, West Nile is a disease of birds that humans are exposed to after a mosquito has fed on an infected bird. Humans can only contract it from mosquitoes and cannot pass it to other humans. For more information about West Nile Virus, visit the CDC website: According to the health department, here are the common symptoms: Headache. Fever. Muscle and joint aches. Nausea. Fatigue. Symptoms involving the central nervous system can also develop, which include neck stiffness, stupor, disorientation, coma, tremors, convulsions, muscle weakness, and paralysis. According to the health department, most infected people show no symptoms, with most recovering on their own. Currently, there are no medications or vaccines to prevent or treat infection. People over 50 years old and those with other health issues are at a higher risk of becoming seriously ill. If people have symptoms and suspect West Nile Virus infection, they should contact their healthcare provider. Individuals can take the following steps to prevent infection this holiday week and throughout summer: Wearing an EPA-registered insect repellant Covering up with long-sleeved shirts and long pants Keeping mosquitoes out of living areas by using air conditioning or intact window screens Limiting outdoor activities during peak mosquito times Dumping standing water around your home As of June 18, there have been no reported human West Nile infection cases or deaths in Lubbock in 2025. Mateo Rosiles is the Government & Public Policy reporter for the Lubbock Avalanche-Journal. Got a news tip for him? Email him: mrosiles@ This article originally appeared on Lubbock Avalanche-Journal: West Nile Virus found in mosquitoes around Lubbock, city urges caution
Yahoo
36 minutes ago
- Yahoo
Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 10 best healthcare penny stocks to buy according to analysts. The company's stock surged 12.1% on June 23 after it announced positive six-month follow-up results from an investigator-sponsored, first-in-human study of its type 1 diabetes treatment. A laboratory cultivating cells for the development of gene and cell therapies. The therapy in focus is UP421, which consists of cadaver-sourced pancreatic islet cells that have been genetically modified using Sana's hypoimmune (HIP) technology to evade immune detection. A significant finding is that the transplanted cells were safe, well-tolerated, survived, and continued to produce insulin in the patient without the need for immunosuppressive medicines. The study identified no safety issues, and the HIP-modified islet cells successfully evaded immune responses (both allogeneic and autoimmune). Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician, and Professor at the Clinic for Uppsala University Hospital, stated that the consistent results at four-week, 12-week, and now six-month follow-ups continue to suggest that a functional cure for type 1 diabetes without immunosuppression is possible. Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company. It develops engineered cell therapies to treat serious diseases, aiming to repair or replace damaged cells. Its platforms include hypoimmune cells, gene delivery, and in vivo cell engineering. Sana's pipeline targets conditions like cancer, type 1 diabetes, and genetic disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None.


Fox News
40 minutes ago
- Fox News
Ancient 'pharaoh's curse' fungus shows promise in killing cancer cells
A potentially deadly fungus known as "pharaoh's curse fungus" could offer an unexpected path to fighting cancer, recent research shows. Scientists from the University of Pennsylvania modified molecules from the fungus — which is officially called Aspergillus flavus — to create a new compound and enhance its cancer-killing properties. "Fungi gave us penicillin," said Dr. Xue (Sherry) Gao, an associate professor at UPenn and leader of the study, in a press release. "These results show that many more medicines derived from natural products remain to be found." The findings were published in the journal Nature Chemical Biology. Aspergillus flavus is found in decaying leaves and compost, as well as on trees, plants and some crops, according to Mayo Clinic. While the fungus doesn't endanger most healthy people, it can cause respiratory issues for those who have weakened immune systems or are taking certain medications. Some of the more severe complications of the fungus can include bleeding in the lungs and life-threatening infections in the brain, heart and kidneys, Mayo Clinic stated. After archaeologists opened King Tut's tomb in the 1920s, multiple members of the excavation team died suddenly, fueling rumors of a "curse" upon those who dared interfere with the pharaoh's rest, according to the UPenn press release. Decades later, doctors hypothesized that fungal spores, which had been dormant for thousands of years, could have infected the team. In the 1970s, it happened again, the university stated. A dozen scientists entered another tomb, this time in Poland — and 10 died within a few weeks. Later investigations were said to reveal the presence of Aspergillus flavus in the tomb. Now, the same fungus linked to King Tut's tomb could have the capability to fight leukemia in a new form of cancer therapy. "There are a variety of compounds able to be produced by fungus," Gao told Fox News Digital. These compounds can be toxic to different cells, she noted, depending on the "biological management we are able to mitigate." The study aimed to find a specific kind of compound — ribosomally synthesized and post-translationally modified peptides, or "RiPPs" — within Aspergillus flavus, which was previously shown to be a good source. When this compound is able to enter cancer cells, Gao said, it may be able to stop their growth. "Cancer cells divide uncontrollably," Gao said in the release. "These compounds block the formation of microtubules, which are essential for cell division." When mixed with human cancer cells, two variants of the molecules within these RiPPS were found to have potent effects against leukemia cells, the researchers found. Another variant performed as well as two FDA-approved drugs that have been used for decades to treat leukemia (cytarabine and daunorubicin). Tiffany Troso-Sandoval, M.D., a medical oncologist and cancer care consultant based in New York, cautioned that this study, which was performed on cell cultures, is still in the very early stages. "It's still very far away from being applicable to use in humans with leukemia," Troso-Sandoval, who was not involved in the study, told Fox News Digital. Speaking about RiPPs, the doctor told Fox News Digital, "What they're referring to [in the study] is basically a rare type of bioactive molecule that they have isolated from this fungus." There are multiple subtypes of leukemia, Troso-Sandoval pointed out, including acute and chronic forms. "One treatment might not work on [another] type of leukemia," she noted. Further testing is needed to determine which subtypes may contain the active molecule. The compound explored in the study had little to no effect on breast, liver or lung cancer cells, the researchers noted. This suggests that its disruptive effects only work on certain types of cells, which will be an important consideration when developing medications. Looking ahead, the researchers plan to test the fungus' potential in animal models and, ultimately, human trials. Gao told Fox News Digital she is "excited about what nature can create and how it can benefit our society." For more Health articles, visit The study received support from the National Institutes of Health, the University of Pennsylvania, the Welch Foundation, the Houston Area Molecular Biophysics Program, the Cancer Prevention and Research Institute of Texas and the National Science Foundation.